
Norris Medicines Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses
2026-10-27 08:53:53Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 26 Oct 2026. This revision reflects deteriorating technical indicators, weak financial trends, poor valuation metrics, and declining quality scores, signalling heightened risk for investors amid a challenging market environment.
Read More
Broad-Based Technical Strength Lifts Norris Medicines Ltd to 52-Week High of Rs 20.06
2026-09-25 09:43:05With a fresh 52-week high of Rs 20.06 reached on 25 Sep 2026, Norris Medicines Ltd has demonstrated notable price momentum, outperforming the broader market which remains subdued near its own lows.
Read More
Broad-Based Technical Strength Lifts Norris Medicines Ltd to 52-Week High of Rs 19.71
2026-09-22 09:44:05Surging to a new 52-week high of Rs 19.71 on 22 Sep 2026, Norris Medicines Ltd has demonstrated remarkable price momentum, outperforming its sector by 4.94% today and extending a seven-day winning streak that has delivered a 35.93% return. This rally stands out amid a broader market environment where the Sensex remains subdued, trading near its 52-week low and below key moving averages.
Read MoreBoard Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday November 14 2026
14-Nov-2026 | Source : BSEOutcome Of Board Meeting Held Today I.E. Saturday November 14 2026
Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2026
14-Nov-2026 | Source : BSEUn-audited financial results for the quarter and half year ended 30th September 2026
Board Meeting Intimation for Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Half Year Ended September 30Th 2026 And Other Matters.
06-Nov-2026 | Source : BSENorris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 inter alia to consider and approve Un-Audited Financial Results For the Quarter and half year ended September 30th 2026 And Other Matters.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available